【摘要】 肺癌是目前当今世界上对人类生命危害最大的恶性肿瘤,其中非小细胞肺癌(NSCLC)占85%以上,大约20%～25%的NSCLC患者可以接受以根治为目的的外科手术。以顺铂为基础的辅助化疗是Ⅱ～Ⅲa期NSCLC完全切除术后的标准治疗方案,但其有效率低、不良反应常难以耐受。晚期NSCLC伴EGFR突变阳性患者使用表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)靶向治疗的疗效确切。近年来,关于早中期NSCLC术后伴EGFR突变阳性辅助EGFR-TKIs治疗的研究结果不断公布,肺癌术后辅助EGFR-TKIs治疗可提高疗效并改善生活质量,但目前仍有所争议。本文拟对近年来国内外关于早中期NSCLC术后辅助EGFR-TKIs靶向药物治疗的疗效和安全性作一综述。更多还原

【Abstract】 Nowadays,lung cancer is currently the most malignant tumor to human life worldwide. Non-small cell lung cancer( NSCLC) accounts for more than 85% of lung cancer,and about 20%-25% of NSCLC patients can receive radical surgery. Cisplatin based adjuvant chemotherapy is the standard treatment for complete resection of stage Ⅱ-Ⅲa NSCLC,but its efficiency is low and adverse reactions are often intolerable. Targeted therapy with epidermal growth factor receptor tyrosine kinase inhibitors( EGFR-TKIs) is effective for advanced NSCLC patients with EGFR mutation. Recently,the results of adjuvant EGFR-TKIs therapy with positive EGFR mutation after early and mid-term NSCLC surgery have been published continuously. The adjuvant EGFR-TKIs treatment after lung cancer surgery can improve the efficacy and quality of life,but there is still some controversy. This article reviews the efficacy and safety of EGFR-TKIs targeted drug therapy in early and mid-term NSCLC surgery at home and abroad in recent years.更多还原